<DOC>
	<DOCNO>NCT02811783</DOCNO>
	<brief_summary>This multi-center , double-blind , vehicle-controlled , randomized crossover design study evaluate safety efficacy topically apply naloxone lotion , 0.5 % , treatment pruritus patient mycosis fungoides ( MF ) form Cutaneous T-cell Lymphoma ( CTCL ) . This study also determine systemic absorption drug subset subject , describe range mean plasma level reach two week three time daily ( TID ) dosing . Funding Source - FDA OOPD</brief_summary>
	<brief_title>Naloxone Hydrochloride Study Relief Pruritus Patients With Mycosis Fungoides ( MF ) Form CTCL</brief_title>
	<detailed_description>There 160 subject enrol study . The study consist Screening Period 7 day inclusion / exclusion criterion review . Subjects meet inclusion / exclusion criterion include diagnostic criterion MF score least 5 11-Point Numeric Rating Scale ( NRS ) Pruritus complete one week Screening Period . Subjects complete daily diary NRS Pruritus score . At end Screening Period , subject NRS Pruritus score least 5 recorded diary least 4 7 day precede Day 0 eligible continue . Baseline assessment record vital sign , pruritic body surface area , skin integrity , laboratory result . The Baseline period follow 2 week Treatment Period 1 subject randomize Naloxone Lotion 0.5 % Placebo Lotion apply TID 14 day . During 2 week Treatment Period subject complete daily diary NRS Pruritis score Sleep score . On Day 14 subject return clinic review diary , adverse event ( AEs ) , concomitant medication , record body surface area pruritus , skin integrity , laboratory result . Subjects enter Washout Period 28 day subject score least 5 NRS Pruritus 4 consecutive 4 past 7 day . Subjects remain eligible enter 2 week Treatment Period 2 procedure Treatment Period 1 perform except subject receive alternate treatment assign Treatment Period 1 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>All subject must meet follow criterion admission study : 1 . Signed informed consent obtain . 2 . Subject least 21 year age . 3 . Diagnosis mycosis fungoides ( MF ) base combination histological , clinical , immunophenotypical criterion . The histological criterion base skin biopsy representative skin area . The diagnostic criterion use subject specified case report form . The skin ( T ) , lymph node ( N ) , visceral involvement ( M ) , blood ( B ) ( TNMB ) system use classify stage disease . 4 . Completion modify severity weight assessment tool ( mSWAT ) assessment . 5 . A history pruritus meet follow criterion : At Screening Day 7 : present daily basis great one month prior Screening Day 7 , NRS Pruritus score ≥5 rat subject Day 7 Visit . At Baseline Period 1 Day 0 : NRS Pruritus score least 5 record subject diary least 4 7 day precede Baseline Period 1 Day 0 . 6 . Pruritic treatment area 595 % subject 's total treatable body surface area . 7 . Subject expect reliably follow treatment instruction visit schedule . 8 . Nonpregnant , nonlactating female childbearing potential agree use medically acceptable form birth control ( abstinence , hormonal contraceptive , diaphragm spermicide , condom spermicide , intrauterine device ) throughout study female nonchildbearing potential ( surgically sterile [ hysterectomy bilateral tubal ligation ] postmenopausal ≥ 1 year ) . A negative urine pregnancy test must confirm Baseline screen female subject postmenopausal &gt; 1 year surgically sterile . 9 . The subject agree begin new concomitant medication participation study , exception medication necessary treat infection . 10 . Subject visual motor impairment make difficult complete Daily Diary apply study medication . 11 . Subject able speak , read , write English agrees participate comply study procedure . 12 . Subject body mass index ( BMI ) 18.5 30.5 kglm2 ( subject pharmacokinetic subset ) . Subjects meet follow criterion exclude study participation : 1 . Pregnant lactate female . 2 . History clinically significant heart failure . 3 . Myocardial infarction within past six month . 4 . A history ventricular arrhythmia require treatment . 5 . A history convulsive disorder . 6 . Any medical condition would , Investigator 's opinion , preclude subject successfully participate study . 7 . A known allergy naloxone hydrochloride excipient formulation . 8 . Previous naloxone use pruritus . 9 . Treatment follow restricted time period prior Baseline , time study , allow : Topical medication Topical alphahydroxy acid skin surface Systemic narcotic analgesic ( e.g . morphine , codeine ) Topical antihistamine skin surface [ e.g . Zonalon® ( doxepin ) ] Systemic antihistamine [ e.g . Allegra® ( fexofenadine ) , Benadryl® ( diphenhydramine ) , Clarinex® ( desloratadine ) , Motrin PM® ( diphenhydramine ) , Tussionex® ( chlorpheniramine ) , Xyzal® ( levocetirizine ) , Zyrtec® ( cetirizine ) ] , Claritin ( loratadine ) ] Topical steroid skin surface Radiation therapy ( e.g . electron beam , narrow band ultra violet B ( UVB ) , systemic topical psoralen ultraviolet A ( PUVA ) ) Other investigational drug ( exclude therapy treatment MF ) 10 . Stable dose/regimen follow treatment allow study subject maintain stable dose/regimen least stated period time entry study continue dose/regimen throughout study . Sedative/hypnotics [ e.g. , Valium® ( diazepam ) , Halcion® ( triazolam ) ] 7 day Tricyclic antidepressant , include monoamine oxidase inhibitor [ e.g. , Eutonyl® ( pargyline ) , Nardil® ( phenelzine ) , Parnate® ( tranylcypromine ) , amitriptyline , nortriptyline , fluoxetine , doxepin ] 30 day Daily systemic corticosteroid ( equivalent ≤ 10mg per day prednisone ) patient erythroderma 30 day Tranquilizers 30 Days Systemic nonnarcotic analgesic nonsteroidal antiinflammatory drug ( NSAIDS ) 30 day All nonmedicated cream , lotion , ointment treatment area 60 day Targretin® ( bexarotene ) 60 day Systemic cytotoxic agent [ e.g . Ontak® ( denileukin diftitox ) , Istodax® ( romidepsin ) , Zolinza® ( vorinostat ) , Trexall ( methotrexate ) , Leukeran ( chlorambucil ) , Toposar ( etoposide ) ] 60 day Photopheresis 3 cycle Alpha interferon 90 day Systemic chemotherapeutic regimen ( include investigational agent ) , carmustine ( BCNU ) , Campath ( alemtuzumab ) 90 day Topical chemotherapeutic agent ( e.g . Nitrogen Mustard preparation , 5FU ) 90 day 3 cycle Systemic oral contraceptive ( e.g . contraceptive implant , strogen/progesterone therapy 90 day</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pruritus</keyword>
	<keyword>Mycosis Fungoides</keyword>
	<keyword>CTCL</keyword>
	<keyword>naloxone</keyword>
	<keyword>opiate antagonist</keyword>
</DOC>